Walleye Capital
GOSS icon

Walleye Capital’s Gossamer Bio GOSS Stock Holding History

Walleye Capital’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-18,700
Closed -$224K – 3349
2022
Q3 		$224K Buy
+18,700
New +$232K ﹤0.01% 2034
2020
Q2 		– Sell
-2,700
Closed -$27K – 757
2020
Q1 		$27K Buy
+2,700
New +$35.3K 0.01% 739

Other funds holding GOSS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Walleye Capital's GOSS Position: Q1 2026 in Review

Walleye Capital sold out of Gossamer Bio (GOSS) in Q1 2026, closing a stake of 1,077,032 shares — an estimated $3.34M sold.

Walleye Capital first reported a position in GOSS in Q1 2020 and held it in 9 quarters. The position peaked at $4.67M in Q2 2022. 185 funds tracked by Wall St. Rank hold GOSS as of Q1 2026.

  • Walleye Capital reported no remaining Gossamer Bio position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 1,077,032 Gossamer Bio shares in Q1 2026, an estimated $3.34M.
  • Walleye Capital first reported a position in Gossamer Bio in Q1 2020 and held it in 9 quarters.
  • Walleye Capital's Gossamer Bio position peaked at $4.67M in Q2 2022.
  • 185 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.